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sents methods to evaluate working ability and quality of life in natalizumab-treated 
RRMS patients. Methods: A non-interventional study was performed in Germany. 
Patients treated with natalizumab for a maximum of three months prior to baseline 
were eligible for study participation. Demographic and occupational information 
was collected; DSS and EQ-5D-questionnaires were used. Data were collected at 
baseline, after 6 months and after 12 months. Main objective was to evaluate pro-
ductivity per year, by using the formula: (working hours per day*5 days per week*46 
working weeks a year) - (days absent from work*working hours per year). To assess 
health economic cost savings, productivity has been valued monetarily by calcu-
lating a daily rate of working costs. Subgroup analysis divides the study popula-
tion into employed, unemployed, patients with statutory sick pay and students. 
Analyses of variance and subsequent post hoc tests will be performed to identify 
subgroup differences. Results: Of 95 patients included by January 2014, 46.3% 
were employed. Average hours worked/day were 5.3 hours (employed: 6.5 hours); 
average number of days absent from work during the past half-year was 17.4 days 
(employed: 16.5 days). Calculated productivity per 6 months results in 569.6 hours 
(employed: 661.0), meaning 6,5540.40€ (employed: 7,634.55€ ) in monetarily valued 
productivity. ConClusions: This non-interventional study aimed at providing new 
insights in the therapy of RRMS patients treated with natalizumab. The study’s 
intention was to show how an increase in working hours in employed patients as 
well as a decrease in days absent from work can lead to an increase in productivity. 
Study was funded by Biogen Idec.
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objeCtives: Teriflunomide is a once-daily oral immunomodulator approved for 
relapsing–remitting MS. The phase 3 TENERE (NCT00883337) study comparing 
teriflunomide with subcutaneous interferon beta-1a (sc IFNβ -1a) did not meet its 
primary endpoint (superiority of teriflunomide vs sc IFNβ -1a on time to treatment 
failure) although there was no difference in annualized relapse rate between teriflu-
nomide 14 mg and sc IFNβ -1a. The objective of the current analysis was to compare 
patient treatment satisfaction of teriflunomide with that of sc IFNβ -1a. Methods: 
Randomized patients (n= 324) received once-daily teriflunomide 14 mg or 7 mg or 
sc IFNβ -1a three times per week; the study was completed 48 weeks after the last 
patient was randomized. Patient satisfaction with treatment was assessed as a 
secondary endpoint using the Treatment Satisfaction Questionnaire for Medication 
(TSQM) version 1.4, a validated generic questionnaire with scores for effective-
ness, side-effects, convenience, and global satisfaction. A mixed-effect model with 
repeated measures was used to analyze TSQM scores at Week 48. Magnitude of 
effects was assessed using effect size (ES), defined as the difference in treatment 
effect divided by standard deviation. The ES differences were ranked as follows: < 0.2, 
negligible; ≥ 0.2–< 0.5, small; ≥ 0.5–≤ 0.8, moderate; > 0.8, high. Results: At Week 48, 
TSQM values showed significantly better patient satisfaction in the teriflunomide 
14-mg group vs the IFNβ -1a group in three domains (side-effects, P< 0.0001; con-
venience, P< 0.0001; global satisfaction, P= 0.02), with no perceived difference on 
effectiveness (P= 0.28). High ES values favoring teriflunomide 14 mg vs IFNβ -1a were 
seen with side-effects (1.09) and convenience (1.81), with a smaller ES for global 
satisfaction (0.39). ConClusions: A significant and meaningful improvement in 
treatment satisfaction for teriflunomide 14 mg vs IFNβ -1a was observed with regards 
to side-effects, convenience, and global satisfaction, which may potentially improve 
treatment adherence and outcomes in clinical practice.
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objeCtives: Analyze real-life AED treatment sequencing in the UK using prescrip-
tion data from the Clinical Practice Research Datalink (CPRD), and compare it to 
the 2012 National Institute for Health and Care Excellence (NICE) clinical guide-
lines. Methods: Patients were included if they had an epilepsy diagnosis and an 
AED prescription between January, 2009 and January, 2014. Patients who entered the 
database untreated were followed from first AED prescription following an epilepsy 
diagnosis, for up to five lines of treatment until being censored at the end of reg-
istration, death, or end of data coverage. Follow-up time could differ substantially 
between patients. AED treatment changes were classified as add, switch, or stop. 
The number of patients per treatment line was calculated for each individual AED 
combination and each regimen, grouped as Monotherapy, Polytherapy, and “No 
AED”. Results: Overall, 8931 patients went through 2469 unique AED treatment 
sequences; 97.1% were started on Monotherapy. 30.8% of patients stayed on their 
first Monotherapy until censored. 16.5% of initial Monotherapy patients switched 
to a second Monotherapy; 27% went to “No AED”; 25.7% progressed to Polytherapy. 
The first treatment line was consistent with NICE guidelines for 70.4% of patients. 
Thereafter, 14.7% of patients were treated within guidelines in the first 2 lines. 
The main divergence from guidelines involved prescribing Polytherapy or “No 
AED” rather than a second monotherapy in line 2. Largely consistent with NICE, 
the most frequent (87.1%) initial monotherapy AEDs were valproic acid (30.1%), 
lamotrigine (22.8%), carbamazepine (17.5%), levetiracetam (10.3%), and phenytoin 
loss and resource were similar in Brazil and the 5EU (all p> 0.05). After adjustments 
(combined 5EU and Brazil), as the number of seizures decreased, PCS (≥ 1 seizures/
week: 40.9; 1-3 seizures/month: 41.7; 1-4 seizures/year: 46.9; < 1seizures/year: 48.4) 
and health utilities (≥ 1 seizures/week: 0.58; 1-3 seizures/month: 0.63; 1-4 seizures/
year: 0.63; < 1seizures/year: 0.69) increased. As the number of seizures decreased, 
activity impairment (≥ 1 seizures/week: 58.6%; 1-3 seizures/month: 51.1%; 1-4 sei-
zures/year: 35.7%; < 1seizures/year: 25.5%), emergency room visits and hospitaliza-
tions decreased. In Europe direct and indirect costs were highest for the ≥ 1 seizure/
week group. ConClusions: POS burden was similar in Europe and Brazil. As the 
number of seizures increased, economic and humanistic burden increased. Even 
with the large number of treatment options available, patients and the health care 
system need additional choices to reduce the frequency of seizures.
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objeCtives: Mobility impairments affect most multiple sclerosis (MS) patients 
(93%), yet many patients (~40%) “rarely or never” discuss trouble walking with a 
health care provider (HCP). To facilitate patient-HCP dialogue and early identifica-
tion of mobility impairments, the Early Mobility Impairment Questionnaire (EMIQ) 
was developed based on qualitative research with patients diagnosed with MS and 
in collaboration with key opinion leaders. To minimize the burden associated with 
administration of the EMIQ, psychometric analyses were applied to the initial draft 
to produce a parsimonious yet robust instrument. Methods: The EMIQ’s psycho-
metric performance was evaluated in a multi-center, prospective, observational 
study in subjects with an Expanded Disability Status Scale (EDSS) score of 2.0 to 
6.0. Iterative exploratory factor analysis (EFA) was used to guide item reduction; 
subsequently, an item response theory (IRT) graded response model was applied to 
confirm the robustness of the instrument. Logistic regression analyses (using EDSS 
scores) were used to confirm discriminatory power. Results: In total, 124 subjects 
with moderate MS (EDSS mean score = 4.2) were included in the study. Discriminant 
validity, factor analysis, and IRT modeling identified six items for reduction. The 
resulting 9-item scale had one strong underlying domain (first eigenvalue explained 
60% of variance). The information curve showed sufficient sensitivity (I> 3.3 for 
-2.6≤ θ ≤ 2.4) throughout the scale (mild to severe), with the most precise informa-
tion provided at ½ SD above the mean (I= 12 at θ = 0.4). Logistic regression showed 
that the EMIQ was able to discriminate between patients with and without walk-
ing impairment (p< 0.05). ConClusions: The psychometric analyses resulted in a 
streamlined scale that is appropriate for the screening of subjects experiencing early 
mobility impairments due to MS. In addition to a potential role in guiding clinical 
assessment and intervention, the EMIQ may also prove useful in the longitudinal 
assessment of mobility, as patients’ conditions decline.
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objeCtives: The impact of Cognitive Impairment (CI) on Health Related Quality 
of Life (HRQoL) in patients with Relapsing Remitting Multiple Sclerosis (RRMS) 
is becoming a field of study increasingly relevant due to its implications on the 
effectiveness and quality research. Since the studies reviewed highlight contra-
dictory results, the aim of this study was to determine the predictive value of CI 
and other correlated factors on HRQoL in a sample of RRMS patients. Methods: 
Observational, cross-sectional and multicenter study at 21 Neurology Departments 
in Spain. Multiple linear regression analysis (stepwise) was carried out to 
assess if HRQoL (EQ-5D scores) was predicted by CI (Brief Repeatable Battery of 
Neuropsychological Tests, BRB-N), physical disability (Expanded Disability Status 
Scale -EDSS), depression (Beck Depression Inventory-BDI-II) and disease duration 
(years diagnosed). Bivariate, partial and semi-partial correlations and multicol-
linearity analysis were performed to control confounding factors. Results: We 
included 291 RRMS patients (71.50% female), mean age 41.65 years (SD= 10.18). The 
mild disability group (EDSS 0-3) included 152 (52.20%) patients and the moder-
ate disability group (EDSS 3.5-5.5) included 139 patients (47.80%). All correlations 
between EQ-5D scores and BRB-N, BDI-II, EDSS and disease duration variables were 
statistically significant (p< 0.01), not multicollinearity detected. The results of the 
regression analysis indicated that two predictors explained 56.9% of the HRQoL 
variance (Adjusted R squared= 0.569, F= 187,251, p< 0.01). It was found that depres-
sion significantly predicted HRQoL (Beta= -0.587, p< 0.01), as did physical disability 
(Beta= -0.315, p< 0.01). ConClusions: The results showed a weak predictive value 
of CI (measured with the BRB-N battery) in HRQOL scores while depression and 
psychical disability were important predictors. Future research is needed in order 
to clarify the relationship between CI and HRQoL.
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objeCtives: Relapsing remitting multiple sclerosis (RRMS) is a chronic inflam-
matory disease representing the most common chronic neurological disorder in 
young adults. RRMS usually leads to permanent disability and as a result is a major 
cause of reduced working capacity due to neurological diseases. This abstract pre-
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evidence were extracted. Results: Our search identified 19 submissions, all of 
which included a placebo-controlled trial, and all except dimethyl fumarate also 
included a head-to-head trial against one of the beta-interferons but not any other 
therapies. Indirect comparisons against old and newer DMTs were also included 
in the submissions. Approximately 90% of appraisals received positive recom-
mendations; reasons for positive recommendations included recognition that 
there is a need for additional treatment options in MS, particularly for patients 
who do not have an adequate response to beta-interferons, and that oral DMTs 
represent an innovative step in the treatment of MS. However, submissions were 
generally criticised for trial design, scarcity of head-to-head trials, use of EDSS 
to measure disability, the uncertainty regarding long-term clinical and economic 
outcomes, and the heterogeneity of trial populations included in indirect compari-
sons. ConClusions: Due to the changing treatment landscape and the popula-
tion included in MS trials, it is clear that placebo-controlled trials and the inclusion 
of beta-interferon trials in indirect comparisons are becoming less suitable for the 
evaluation of new MS treatments. Future HTA submissions will need to take into 
account the need to demonstrate superiority over comparators, and manufactur-
ers and regulators will need to work together to develop new and reliable measures 
that can evaluate MS symptoms and impairments in the context of DMTs.
PND78
coMPariNg characteriSticS of huNgariaN “real life” PatieNtS with 
ParticiPaNtS of rctS: firSt-liNe DiSeaSe MoDifyiNg theraPieS iN 
MultiPle ScleroSiS
Foldesi C.1, Penzes M.2, Szabo M.2
1National Institute of Quality and Organizational Development in Healthcare and Medicines, 
Budapest, Hungary,, 2National Health Insurance Fund, Budapest, Hungary
objeCtives: Health technology assessment and decision making process lean 
on evidences provided by RCTs. Our aim was to compare the characteristics of 
Hungarian patients with multiple sclerosis to the participants enrolled in pivotal 
trials of first-line DMTs. Methods: The database of the National Health Insurance 
Fund was used for analyze the attributes of all MS patients starting first-line DMTs 
between 2008 and 2013. We investigated the following characteristics: 1. age, 2. 
gender ratio, 3. time since first MS symptoms, 4. time since first MS diagnosis, 
5. number of relapses in 2 years prior to therapy. For the comparison we summarized 
phase III RCTs of interferon beta-1a and 1b, glatiramer-acetate, teriflunomide and 
dimethyl-fumarate. Results: A total of 3877 Hungarian MS patients were involved 
and 1670 were selected for analysis after excluding the population of the year of 
DMT inclusion. The mean age was 36.18±9.96 years which resembles to the par-
ticipants of old immunomodulatory drugs (≈36 years) and slightly younger than 
the patients of the trials with new therapies (≈38 years). There was no difference 
in gender ratio (≈70% female). While in the RCTs the mean time since first symp-
toms was longer than the mean time since first diagnosis (≈7–8 vs ≈5.5 years), in 
the Hungarian patients these two values did not differ significantly (3.30±3.80 vs 
3.17±3.77 years). We suspect that the reason for this unexpected difference can be 
explained by the imprecise use of ICD codes in Hungarian clinical practice. The 
relapse rate per 2 years seemed to decline in trials of the last two decades from 3 to 
2-2.5 which is equal to the Hungarian patients. ConClusions: The population of 
RCTs represents the Hungarian MS patients in certain aspects but not completely. 
Our analysis can help the adaptation of international models to local circumstances 
in HTA of forthcoming MS therapies.
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objeCtives: Disease Modifying Treatments (DMTs) to manage Relapsing Remitting 
Multiple Sclerosis (RRMS) patients have traditionally been injectables. With the 
introduction of new oral DMTs, a better understanding of the shift in treatment 
patterns and their impact on patient disease burden is needed. The objective of 
this study was to assess the characteristics of RRMS patients taking injectable 
and oral DMTs in the United States (US). Methods: A multi-center retrospective 
chart-review study of RRMS patients was conducted in the US in 4Q2013 to collect 
de-identified data on diagnosis, clinical status, and treatment patterns. Physicians 
were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 MS patients/
mo and recruited from a large panel to be geographically representative. Medical 
charts of the next 10 consecutive MS patients were abstracted. RRMS patients taking 
an injectable (INJ) or oral DMT were analyzed. Results: 561 eligible RRMS patients 
were included in the analysis (INJ: 66%; Oral: 34%). Patient characteristics were (INJ/
Oral): age: 41/40yrs, female: 71%/70%, time since diagnosis: 62/53mo, time between 
diagnosis and initiation of first DMT: 5/3mo, percent on first, second, and third line 
DMT were (INJ/Oral): 78%/30%, 18%/45%, and 4%/25%; time on current DMT (INJ/
Oral): 47mo/6mo. Reasons for current DMT initiation included (INJ/Oral): efficacy 
against relapses (32%/27%)/efficacy in slowing progression (24%/23%)/efficacy in 
early MS (21%/4%)/patient decision (7%/17%)/oral administration (0%/17%). Patient 
JCV status (INJ/Oral): positive-3%/23% & not tested-75%/46%; number of gadolinium-
enhanced & T2 lesions: 0.8/1.3 & 7.7/10.3; percent with ≥ 1 relapse in past 12mo: 
42%/66%; percent with Expanded Disability Status Scale score of ≥ 4.5: 15%/31%; 
percent with moderate-to-severe disability per physician judgment: 22%/40%; per-
cent with active or highly active disease per physician judgment: 37%/60%; percent 
with moderate-to-severe disease per physician judgment: 22%/44%. ConClusions: 
In this cohort of RRMS patients, physicians initiated oral DMTs predominantly as 
second or third-line treatment, and these patients may have higher disease bur-
den compared to those receiving injectable DMTs. Further research is needed to 
evaluate the observed treatment patterns and treatment sequencing strategies to 
alleviate patient burden.
(6.4%). ConClusions: These data suggest that, after initial monotherapy, a major-
ity of epilepsy treatment decisions do not follow 2012 NICE guidelines, with the 
degree of divergence increasing through lines of therapy. These results call for more 
detailed investigation into treatment patterns and the reasons for divergence from 
clinical guidelines in epilepsy.
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objeCtives: Progression of symptoms among Relapsing Remitting Multiple 
Sclerosis (RRMS) patients may necessitate active disease management. The objective 
of the study was to assess the patterns of use of tests to monitor disease activity/
progression in RRMS in EU and US, based on disease severity. Methods: A multi-
center retrospective chart-review study of MS patients was conducted in EU (UK/
France/Germany/Italy/Spain) and US to collect de-identified data on diagnosis, clini-
cal status, and disease management approaches. Health care providers (HCPs; 94% 
neurologists) were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 
MS patients/mo) and recruited from a large panel to be geographically representative 
in each country. Medical charts of next 10 consecutive MS patients were abstracted 
by each HCP. RRMS patient data was analyzed. Results: 2433 eligible RRMS patient 
charts were abstracted by 365 HCPs (EU/US: N= 265/100; mean neurology practice 
duration= 17/21yrs; mean number of patients seen per month= 66/62). In EU/US, 
patient mean age: 37/41yrs, female: 67%/70%, currently treated: 85%/88%, currently 
with mild: moderate: severe disease-60%: 34%: 5%/67%: 29%: 3%. Top-5 tests used 
to monitor RRMS varied between the regions overall as well as by patient disease 
severity (EU/US: %patients): Neurological exam: overall-83/88, mild-80/89, moder-
ate-87/86, severe-91/90; Gadolinium MRI: overall-62/71, mild-57/71, moderate-69/71, 
severe-77/70; T2 MRI: overall-62/73, mild-59/74, moderate-66/70, severe-64/75; T1 
MRI: overall-53/62, mild-51/64, moderate-55/58, severe-59/70; Expanded Disability 
Status Scale (EDSS): overall-86/29, mild-87/29, moderate-86/30, severe-80/35. 
Percent with unknown Gd-enhanced lesions were (EU/US): overall-33/40, mild-
37/42, moderate-29/37, severe-17/25. Percent with unknown T2 lesions were (EU/
US): overall-33/35, mild-34/36, moderate-32/34, severe-17/20. UK HCPs reported 
substantially more patients with unknown Gd-enhanced (70%) and T2 lesions 
(66%). ConClusions: Besides neurological exam and EDSS, MRI testing is widely 
used and its use increased with increasing disease severity (EU only); the percent 
of patients with unknown lesions decreased correspondingly. Still, one-third of 
patients had unknown lesions (with UK reporting two-thirds), warranting further 
scrutiny on practice patterns and diagnostics to optimize available therapeutic 
choices and alleviate disease burden.
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objeCtives: The aim of our study is to assess amount and frequency of the physi-
otherapy services in the different neurology diseases within out-patient care in 
Hungary. Methods: The data come from the nationwide, financial data base of 
the National Health Insurance Fund Administration covering the official reports 
of outpatient care institutes in 2009. The total numbers of different physiotherapy 
services were determined by selecting the reported specific diagnoses codes and 
counting the number treatments provided for that specific diagnosis code. The dis-
eases of the nervous system are listed in the International Classification of Diseases 
(ICD) with code of G00-G99. Results: The total number of the 151 different types 
WHO-classified physiotherapy procedures was 32318413; and 1331675 (4.12%) of 
them related to neurology care with the ICD code group G00-G99. The amount and 
frequency of the physiotherapy services are in the different neurology diseases are 
the following: Inflammatory diseases of the central nervous system 3584 (0.26%), 
Systemic atrophies primarily affecting the central nervous system 7265 (0.52%), 
Extrapyramidal and movement disorders 82923 (5.96%), Other degenerative diseases 
of the nervous system 15717 (1.13%), Demyelinating diseases of the central nervous 
system 30300 (2.18%), Episodic and paroxysmal disorders 191909 (13.80%), Nerve, 
nerve root and plexus disorders 438780 (31.56%), Polyneuropathies and other disor-
ders of the peripheral nervous system 96871 (6.97%), Diseases of myoneural junction 
and muscle 21276 (1.53%), Cerebral palsy and other paralytic syndromes 434550 
(31.26%), Other disorders of the nervous system 67024 (4.82%). ConClusions: The 
diseases of the nervous system showed different utilization frequency in physi-
otherapy services and represent a significant burden for the health care system.
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objeCtives: In recent years, a number of new DMTs for the treatment of MS 
have been approved by the FDA and EMA, specifically fingolimod, dimethyl 
fumarate, teriflunomide, and alemtuzumab. This study evaluated the HTA 
appraisals for these DMTs to identify any trends or future opportunities in 
MS. Methods: HTA appraisals for fingolimod, dimethyl fumarate, terifluno-
mide, and alemtuzumab from NICE (England), SMC (Scotland), CADTH (Canada), 
PBAC (Australia), HAS (France), TLV (Sweden) and IQWiG (Germany) were iden-
tified. Recommendations, reasoning, and the supporting clinical and economic 
